Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06361888
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-03-26
Brief Title:
A Phase IIIII Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
Sponsor:
Hutchmed
Organization:
Hutchmed
Study Overview
Official Title:
A Multicenter Randomized Open-label Active-controlled Phase IIIII Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of Surufatnib combined withcamrelizumab nab-paclitaxel and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
Detailed Description:
This is a multicenter randomized open-label active-controlled phase IIIII trial to evaluate the efficacy and safety of surufatinib combined with camrelizumab nab-paclitaxel and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None